Fespixon has passed the preliminary review by the National Healthcare Security Administration of China

Published Date:2024-08-07

Original Link:https://www.onenessbio.com/en/news_detail309_2.htm

Statement
No	1	Date of announcement	2024/08/07	Time of announcement	20:05:43
Subject	Fespixon has passed the preliminary review by the National Healthcare Security Administration of China
To which item it meets	paragraph 53			Date of events	2024/08/07
Date of occurrence of the event: 2024/08/07 Company name: ONENESS BIOTECH CO., LTD. Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office Reciprocal shareholding ratios: NA Cause of occurrence: According to ”National Reimbursement Drug List 2024” announced by The National Healthcare Security Administration of China, Fespixon has passed the preliminary review to negotiable drug. Countermeasures: None Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): (1)In accordance with ”National Reimbursement Drug List (NRDL) 2024 Work Plan”, and the ”National Reimbursement Drug List 2024 Application Guidelines”, the National Healthcare Security Administration of China has completed the preliminary review on the qualification of drugs applied to be included in NRDL list and announced the qualified list of negotiable drugs. (2)Passing the preliminary review on negotiable drug qualification does not mean the inclusion in the formulary of National Reimbursement Drug List. Expert review, price negotiation, and subsequent steps will be proceeded according to procedures.